MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
2.910
-0.560
-16.14%
After Hours: 3.160 +0.25 +8.59% 19:59 05/22 EDT
OPEN
3.150
PREV CLOSE
3.470
HIGH
3.250
LOW
2.840
VOLUME
124.99K
TURNOVER
--
52 WEEK HIGH
241.50
52 WEEK LOW
2.530
MARKET CAP
1.76M
P/E (TTM)
-0.0036
1D
5D
1M
3M
1Y
5Y
1D
Jaguar Animal Health Adjourns 2026 Annual Shareholder Meeting
TipRanks · 1d ago
Jaguar Health GAAP EPS of -$13.60, revenue of $20.27M
Seeking Alpha · 3d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 3d ago
Jaguar Health Reports Q1 2026 Revenue Surge Driven By Licensing Deal
NASDAQ · 3d ago
Jaguar Health Q1 EPS $(13.60) Misses $(4.26) Estimate, Sales $20.272M Beat $4.211M Estimate
Benzinga · 3d ago
Jaguar Health reports Q1 EPS ($13.60) vs. ($584.45) last year
TipRanks · 4d ago
JAGUAR HEALTH INC - Q1 NET LOSS $7.0 MLN VERSUS $10.5 MLN YEAR AGO - SEC FILING
Reuters · 4d ago
JAGUAR HEALTH INC - Q1 NET REVENUE $20.3 MLN- SEC FILING
Reuters · 4d ago
More
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Webull offers Jaguar Health Inc stock information, including NASDAQ: JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.